Payment overview · 2025
General Payments
$1,224.59
73 reported records · 24 companies
Healthcare provider profile · identity verified
Dushyant Parikh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ENFIELD, CT · NPI 1023033008
Verified facts
What the public records show
CMS Open Payments records show Dushyant Parikh, M.D. received $1,224.59 in general payments during 2025 across 73 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Eliquis, Entresto, Gemtesa, Jardiance, Kerendia, Mounjaro, Rexulti, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Vraylar by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rytary by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 390 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1143 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1143 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $245.06 | 20.0% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $164.14 | 13.4% | 21 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $138.38 | 11.3% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $77.10 | 6.3% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $70.52 | 5.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $69.42 | 5.7% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.49 | 3.7% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $44.05 | 3.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $40.20 | 3.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.93 | 2.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.61 | 2.8% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.02 | 2.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.04 | 2.0% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $23.09 | 1.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.64 | 1.7% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.69 | 1.6% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $19.26 | 1.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.23 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.14 | 1.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.01 | 1.6% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.66 | 1.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.98 | 1.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.91 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.02 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,224.59 | 73 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $230.31 | 5 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $173.11 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $158.36 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $138.38 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $99.37 | 13 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $85.40 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $70.52 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.77 | 8 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $59.97 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.93 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $45.49 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $44.05 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.20 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.93 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.93 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $34.66 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $33.02 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $26.15 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.04 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $6.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1143 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 147 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 115 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 223 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 37 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 192 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
390 | 44 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
37 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
223 | 17 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1143 | 82 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
192 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
223 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
147 | 15 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
18 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1143 | 82 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 24 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
115 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2428 | 266 |
| Levothyroxine Sodium | Levothyroxine Sodium | 2075 | 169 |
| Trazodone Hcl | Trazodone Hcl | 1893 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 1759 | 197 |
| Gabapentin | Gabapentin | 1273 | 102 |
| Sertraline Hcl | Sertraline Hcl | 1202 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1183 | 127 |
| Furosemide | Furosemide | 1163 | 112 |
| Eliquis | Apixaban | 1143 | 82 |
| Mirtazapine | Mirtazapine | 1002 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 995 | 104 |
| Escitalopram Oxalate | Escitalopram Oxalate | 980 | 60 |
| Metformin Hcl | Metformin Hcl | 814 | 95 |
| Donepezil Hcl | Donepezil Hcl | 793 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 752 | 150 |
| Metoprolol Tartrate | Metoprolol Tartrate | 709 | 77 |
| Lisinopril | Lisinopril | 704 | 106 |
| Losartan Potassium | Losartan Potassium | 647 | 53 |
| Omeprazole | Omeprazole | 629 | 65 |
| Potassium Chloride | Potassium Chloride | 591 | 53 |
| Prednisone | Prednisone | 585 | 93 |
| Tamsulosin Hcl | Tamsulosin Hcl | 551 | 61 |
| Simvastatin | Simvastatin | 543 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 535 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 471 | 21 |
| Farxiga | Dapagliflozin Propanediol | 390 | 44 |
| Ezetimibe | Ezetimibe | 365 | 55 |
| Famotidine | Famotidine | 343 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 331 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 327 | 27 |
| Torsemide | Torsemide | 313 | 29 |
| Montelukast Sodium | Montelukast Sodium | 306 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 305 | 30 |
| Myrbetriq | Mirabegron | 302 | 20 |
| Memantine Hcl | Memantine Hcl | 291 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 272 | 82 |
| Buspirone Hcl | Buspirone Hcl | 269 | 21 |
| Xarelto | Rivaroxaban | 251 | 17 |
| Valsartan | Valsartan | 234 | 30 |
| Baclofen | Baclofen | 231 | suppressed |
| Spironolactone | Spironolactone | 231 | 17 |
| Jardiance | Empagliflozin | 223 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 218 | 34 |
| Carvedilol | Carvedilol | 215 | 36 |
| Divalproex Sodium | Divalproex Sodium | 212 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 212 | 24 |
| Januvia | Sitagliptin Phosphate | 208 | 24 |
| Levetiracetam | Levetiracetam | 201 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 194 | 48 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 192 | 35 |
| Azithromycin | Azithromycin | 183 | 126 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 183 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 27 |
| Meloxicam | Meloxicam | 171 | 28 |
| Tradjenta | Linagliptin | 167 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 163 | 19 |
| Lamotrigine | Lamotrigine | 162 | suppressed |
| Lorazepam | Lorazepam | 154 | 27 |
| Allopurinol | Allopurinol | 151 | 28 |
| Atenolol | Atenolol | 151 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 149 | 14 |
| Entresto | Sacubitril/Valsartan | 147 | 15 |
| Finasteride | Finasteride | 146 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 145 | suppressed |
| Glimepiride | Glimepiride | 140 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 138 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 44 |
| Methocarbamol | Methocarbamol | 136 | 34 |
| Ozempic | Semaglutide | 128 | 20 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 125 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 124 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 16 |
| Tramadol Hcl | Tramadol Hcl | 123 | 40 |
| Warfarin Sodium | Warfarin Sodium | 119 | suppressed |
| Gemtesa | Vibegron | 115 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 114 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 114 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 114 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 112 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 108 | suppressed |
| Glipizide | Glipizide | 106 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 99 | suppressed |
| Folic Acid | Folic Acid | 98 | suppressed |
| Olanzapine | Olanzapine | 95 | suppressed |
| Latanoprost | Latanoprost | 94 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 89 | 43 |
| Midodrine Hcl | Midodrine Hcl | 88 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 86 | suppressed |
| Clonazepam | Clonazepam | 84 | 15 |
| Dilantin | Phenytoin Sodium Extended | 84 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 83 | suppressed |
| Carbamazepine | Carbamazepine | 82 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 77 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 77 | 22 |
| Diltiazem Hcl | Diltiazem Hcl | 76 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 73 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 72 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 71 | 18 |
| Lactulose | Lactulose | 70 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 48 |
| Lovastatin | Lovastatin | 68 | suppressed |
| Nifedipine Er | Nifedipine | 67 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 12 |
| Digoxin | Digoxin | 66 | suppressed |
| Methylprednisolone | Methylprednisolone | 66 | 52 |
| Pregabalin | Pregabalin | 66 | 13 |
| Alprazolam | Alprazolam | 65 | 16 |
| Linzess | Linaclotide | 65 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 62 | suppressed |
| Ibuprofen | Ibuprofen | 60 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 14 |
| Bupropion Xl | Bupropion Hcl | 59 | 14 |
| Glipizide Er | Glipizide | 59 | suppressed |
| Risperidone | Risperidone | 59 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 58 | 45 |
| Topiramate | Topiramate | 58 | suppressed |
| Vascepa | Icosapent Ethyl | 57 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 57 | 19 |
| Amoxicillin | Amoxicillin | 56 | 43 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 56 | 29 |
| Methenamine Hippurate | Methenamine Hippurate | 56 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 55 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 53 | suppressed |
| Riluzole | Riluzole | 53 | suppressed |
| Anastrozole | Anastrozole | 52 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 52 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 52 | suppressed |
| Carbidopa | Carbidopa | 52 | suppressed |
| Carisoprodol | Carisoprodol | 52 | suppressed |
| Galantamine Er | Galantamine Hbr | 52 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 52 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 52 | suppressed |
| Celecoxib | Celecoxib | 50 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 50 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 49 | 29 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Rexulti | Brexpiprazole | 49 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 48 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 46 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 45 | 12 |
| Synthroid | Levothyroxine Sodium | 45 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 35 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Calcium Acetate | Calcium Acetate | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 13 |
| Vraylar | Cariprazine Hcl | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 19 |
| Dapagliflozin | Dapagliflozin Propanediol | 41 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Sucralfate | Sucralfate | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 14 |
| Insulin Lispro | Insulin Lispro | 38 | 11 |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Kerendia | Finerenone | 37 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 35 | 21 |
| Fluconazole | Fluconazole | 35 | 25 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Lumigan | Bimatoprost | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 11 |
| Cephalexin | Cephalexin | 33 | 26 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 30 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 30 | suppressed |
| Humalog | Insulin Lispro | 30 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 28 | suppressed |
| Novolog | Insulin Aspart | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Lubiprostone | Lubiprostone | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 15 |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Ramelteon | Ramelteon | 27 | suppressed |
| Ubrelvy | Ubrogepant | 27 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 26 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 24 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Nystatin | Nystatin | 24 | 12 |
| Restasis | Cyclosporine | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Dulera | Mometasone/Formoterol | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Teriflunomide | Teriflunomide | 22 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 21 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Mesalamine | Mesalamine | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Rytary | Carbidopa/Levodopa | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Mirabegron Er | Mirabegron | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 17 |
| Alphagan P | Brimonidine Tartrate | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Combigan | Brimonidine Tartrate/Timolol | 18 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Desloratadine | Desloratadine | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Tadalafil | Tadalafil | 16 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 15 | 15 |
| Brilinta | Ticagrelor | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 15 | 12 |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 15 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Motegrity | Prucalopride Succinate | 14 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | 11 |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dalfampridine Er | Dalfampridine | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,224.59 · 73 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BEVESPI AEROSPHERE, BREZTRI, CAPLYTA, Cologuard Collection Kit, EDARBI, ELIQUIS, ENTRESTO, FANAPT, GEMTESA, HETLIOZ, IBSRELA, INGREZZA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OPSUMIT, QULIPTA, REXULTI, Repatha, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, UNITHROID, UPTRAVI, VRAYLAR, XIFAXAN, ZEPBOUND, ZORYVE | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error